In a South African cohort of participants living with HIV developing virological failure on first-line tenofovir disoproxyl fumarate (TDF)-based regimens, at least 70% of participants demonstrated TDF resistance according to combined Sanger and MiSeq genotyping. Sanger sequencing missed the K65R mutation in 30% of samples. Unless HIV genotyping is available to closely monitor epidemiological HIV resistance to TDF, its efficacy as second-line therapy will be greatly compromised.
Provision of antiretroviral therapy (ART) in resourcepoor settings employing a public health approach has achieved major successes, saving thousands of lives and averting new HIV infections. Recently, ART initiation in all adults living with HIV disregarding CD4 þ cell count was recommended for the first time in World Health Organization (WHO) HIV treatment guidelines [1] . However, the ART arsenal available to most resourcepoor settings remains limited, and treatment follow-up rarely includes virological monitoring. In this context, antiretroviral resistance remains a major threat to the public health efforts to eradicate the HIV pandemic.
Tenofovir disoproxyl fumarate (TDF), in combination with lamivudine (3TC)/emtricitabine (FTC) and nevirapine (NVP)/efavirenz (EFV), remains an antiretroviral of choice for first-line ART in Africa, being included in the South African national HIV/AIDS treatment plan for naïve patients [2] . Tenofovir has high antiviral potency, allows once-daily dosing (frequently co-formulated) and is well tolerated. However, its efficacy is diminished in the presence of the K65R mutation [3] . Subtype C, the most prevalent subtype in South Africa, selects for this mutation faster than other subtypes due to subtypespecific pathways [4, 5] . This is an important concern because failure to TDF-containing regimens is often associated with additional resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors (NRTI and NNRTI). Therefore, patients developing virological failure to TDF might potentially loose multiple secondline ART options.
Using Sanger sequencing, previous studies reported the emergence of K65R mutation in 23-69.7% of participants developing virological failure to first-line TDF regimens [6] [7] [8] [9] . The true prevalence of TDF resistance, however, might have been underestimated by the lack of sensitivity of standard Sanger-based genotyping methods. Achieving a precise estimate of TDF resistance after virological failure of first-line TDF regimens is also key to inform public policy as to whether TDF might be reused in second-line ART or subsequent regimens. Transmission of TDF resistance might also potentially compromise the efficacy of PrEP strategies [1] .
To evaluate the prevalence of TDF resistance using ultrasensitive sequencing methods, we developed a retrospective reanalysis of participants developing virological failure to TDF within a larger cohort study conducted at the McCord Hospital, Durban, South Africa. All participants developing virological failure to first-line ART including TDF þ 3TC plus an NNRTI received a genotypic resistance test using a validated inhouse Sanger-based sequencing assay in Durban, South Africa. Plasma samples from those with no K65R mutation by Sanger sequencing were reanalyzed at the irsiCaixa AIDS Research Institute in Badalona, Spain using MiSeq Illumina (Illumina Inc., California, USA).
In brief, the complete pol gene was amplified and sequenced in a MiSeq platform using a Nextera-XT shotgun approach. A 1% threshold level was chosen for detection of minority variants. MiSeq had the K65R mutation, a conservative estimate of the overall prevalence of K65R mutation was 69.6%, which is a 10.1% increase in prevalence relative to Sanger sequencing. Prevalence was calculated using only TDFfailing and PCR-success patients.
In addition, deep sequencing detected IAS-USA mutations missed by Sanger in 22 out of 27 patients (81.4%) at frequencies in the range 1.1 -35.7% in the virus population (Table 1) . Such additional mutations changed the predicted drug susceptibility in 15 out of 27 patients (55.5%), mostly affecting TDF, etravirine (ETR) and rilpivirine (RPV), although the predicted susceptibility to NVP or EFV was not affected ( Our findings confirm initial estimations that TDF might lose antiviral efficacy in virtually all patients infected with a subtype C HIV developing virological failure to this drug. Thereby, unless HIV genotyping is available to ensure that HIV remains susceptible to TDF, the use of this drug will be greatly compromised in efficacy for second-line therapy, and should not be prescribed except if no other treatment options are available. Continued surveillance of primary resistance in Africa is key to survey transmission of TDF-resistant mutants to newly HIV-infected patients, which could impact the efficacy of both first-line ARTand PrEP [10, 11] . To date, rates of virological failure to firstline TDF regimens and transmission of K65R mutants have remained low according to Sanger sequencing estimates [12, 13] . The fitness cost of the K65R mutation, however, makes K65R mutants wane and thus might be missed by Sanger methods.
Another remarkable finding of our study was that, in addition to identifying K65R, additional resistance mutations detected with MiSeq relative to Sanger mainly affected the predicted susceptibility to the secondgeneration NNRTIs ETR and RPV, but did not largely influence viral susceptibility to other antiretrovirals, including AZT. On the one hand, this suggests that ETR and RPV might not be good options for secondline ARTregimens following EFVor NVP failure. On the other hand, our findings support AZT as a second-line drug in South Africa, used in combination with 3TC and LPV or other protease inhibitors [2] or even integrase inhibitors. Whereas routine drug resistance testing may help decide which NRTIs to use in second-line therapy, the EARNEST trial recently showed that, even without this information, second-line regimens including boosted protease inhibitor plus two NRTIs retained better virological outcomes than protease inhibitor monotherapy, even in the presence of high-level resistance to the NRTI backbone [14] , suggesting that residual NRTI activity may be sufficient when combined with highly potent boosted protease inhibitor-based therapy.
Despite its limitations -including a small sample size, lack of adherence data and the inclusion of patients under clinical care which might not represent the general South Africa population -this study not only confirms the development of TDF resistance in most patients developing TDF failure in South Africa, but also supports current public health algorithms for HIV clinical management.
